The technology arm of Ping An Insurance Group has completed clinical trials for its retinal disease screening system. In a press release on Tuesday, the company said it had successfully tested the system in patients with macular degeneration (AMD), which is caused by damage to one or more layers of cells that are responsible
The technology arm of Ping An Insurance Group has completed clinical trials for its retinal disease screening system. The intelligent optical coherence tomography (OCT) system is believed to be the first to integrate AI detection in an OCT retinal imaging device, and was jointly developed with US-based Optovue.